Higano C - Search Results

1

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.

Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Va… See abstract for full author list ➔ Gillessen S, et al. Among authors: higano c. Eur J Cancer. 2023 May;185:178-215. doi: 10.1016/j.ejca.2023.02.018. Epub 2023 Mar 3. Eur J Cancer. 2023. PMID: 37003085 Free article.

2

Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.

Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M 3rd, Sellers WR, Smith MR, McMann MC, Kantoff PW. Carroll PR, et al. J Urol. 2003 Dec;170(6 Pt 2):S3-5. doi: 10.1097/01.ju.0000095101.18470.a0. J Urol. 2003. PMID: 14610403 Review. No abstract available.

3

Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer.

Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ. Higano CS, et al. Clin Cancer Res. 2004 Feb 15;10(4):1219-25. doi: 10.1158/1078-0432.ccr-1404-02. Clin Cancer Res. 2004. PMID: 14977818 Clinical Trial.

4

Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.

Beer TM, Garzotto M, Lowe BA, Ellis WJ, Montalto MA, Lange PH, Higano CS. Beer TM, et al. Clin Cancer Res. 2004 Feb 15;10(4):1306-11. doi: 10.1158/1078-0432.ccr-1021-03. Clin Cancer Res. 2004. PMID: 14977829 Clinical Trial.

5

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Diamond TH, et al. Cancer. 2004 Mar 1;100(5):892-9. doi: 10.1002/cncr.20056. Cancer. 2004. PMID: 14983482 Free article. Review.

6

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.

Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS. Smith MR, et al. Among authors: higano cs. J Clin Oncol. 2005 May 1;23(13):2918-25. doi: 10.1200/JCO.2005.01.529. J Clin Oncol. 2005. PMID: 15860850 Clinical Trial.

7

Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer.

Garzotto M, Myrthue A, Higano CS, Beer TM. Garzotto M, et al. Urol Oncol. 2006 May-Jun;24(3):254-9. doi: 10.1016/j.urolonc.2005.11.034. Urol Oncol. 2006. PMID: 16678060 Clinical Trial.

8

The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.

Saad F, Higano CS, Sartor O, Colombel M, Murray R, Mason MD, Tubaro A, Schulman C. Saad F, et al. Among authors: higano cs. Clin Genitourin Cancer. 2006 Mar;4(4):257-62. doi: 10.3816/CGC.2006.n.004. Clin Genitourin Cancer. 2006. PMID: 16729908 Review.

9

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Small EJ, et al. J Clin Oncol. 2006 Jul 1;24(19):3089-94. doi: 10.1200/JCO.2005.04.5252. J Clin Oncol. 2006. PMID: 16809734 Clinical Trial.

10

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.

Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW; ASCENT Investigators. Beer TM, et al. J Clin Oncol. 2007 Feb 20;25(6):669-74. doi: 10.1200/JCO.2006.06.8197. J Clin Oncol. 2007. PMID: 17308271 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

324 results

Search Page